API | lumiracoxib

lumiracoxib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Now

Lumiracoxib is a COX-2 selective inhibitor nonsteroidal anti-inflammatory drug. ^Wikipedia

Chemistry

SMILES: Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
InChIKey: KHPKQFYUPIUARC-UHFFFAOYSA-N
Mol. Mass: 293.73
ALogP: 4.16 Partition coefficient
ChEMBL Molecule:
lumiracoxib

More Chemistry

Pharmacology

Mechanism of Action:
- Prostaglandin G/H synthase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid | 2-((2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid | cox189 | cox 189 | cox-189 | joicela | lumiracoxib | lumiracoxibum | prexige

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (12)

Approved Indications (1)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Arthralgia (Phase 2)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 3)

Healthy Volunteers (Phase 4)

Hypertension (Phase 4)

Kidney Failure, Chronic (Phase 2)

Musculoskeletal Pain (Phase 4)

Osteoarthritis (Phase 4)

Osteoarthritis, Hip (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pain (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 17
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue